...A. Following eplontersen's positive Phase II results in ATTR polyneuropathy, we look forward to approval in the U.S. in December. B. And we expect to complete enrollment in the eplontersen Phase III CARDIO-TTRansform study in patients with ATTR cardiomyopathy soon. C. For olezarsen, we expect results from the FCS BALANCE study in the second half of the year, while enrollment in our registrational studies for the larger sHTG indication continued to progress. D. For donidalorsen, we just completed enrollment in our OASIS-HAE Phase III study, keeping us on track for data in the first half of next year. E. And we're well on our way with our preparations to launch all 3 of these drugs. F. And the rest of our late-stage Phase III pipeline is also performing well and has recently expanded to 8 drugs advancing to treat 10 separate indications. G. And tofersen, now referred to as QALSODY was recently approved in the U.S. for the treatment of SOD1-ALS, joining SPINRAZA as our second approved medicine...
